QualityStocks would like to highlight
Zenosense, Inc. (
OTCQB: ZENO). The company is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
In the company’s news,
Zenosense reported on the status of development operations for its MRSA and lung cancer detection devices. Development efforts have been moving forward as planned. In its news release, Zenosense disclosed the following summarized recent achievements:
MRSA/SA
• A new sensor has been defined for manufacturing. It includes a new MRSA/SA VOC (Volatile Organic Compound) biomarker micro-separator technology.
• For this new technology, tests have been initiated to measure and contrast cultures of MRSA and SA.
• Electronics design for a microbiology lab device is complete, and industrial design for the device is in process.
• The electronics and new sensor are expected to be integrated in the coming weeks to produce the first prototype for laboratory detection of MRSA/SA in cultures.
Lung Cancer
• First tests using a LC VOC biomarker selected from existing hospital research data have been carried out.
• Good sensitivity to this VOC biomarker using the current sensor has been obtained, the VOC biomarker typically being expressed by LC patients at levels well within the capability of the sensor.
• Further tests will be carried out with the intent to resolve issues with cross-sensitivity with other VOC biomarkers and other ambient compounds.
• A review of literature and current research is in hand with alternative VOC biomarkers identified.
• A device for clinical tests with lung cancer patients has been designed, including electronics and a VOC capturing system. It is intended for this device to meet hospital clinical procedure requirements.
With its respected partner Sgenia Group, Zenosense seeks to develop effective medical devices targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. It intends to market and sell these products to hospitals and primary healthcare facilities. Intended for the timely detection of Methicillin-resistant Staphylococcus aureus “Super-Bug” (MRSA) and lung cancer, these devices incorporate an advanced electronic nose technology to identify VOC signatures given by patients with this infection/illness.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
